Welcome to Viteava

We are a start-up drug development company focused on addressing significant unmet medical needs in women’s health and cancer.

Green tea consumption has long been associated with numerous health benefits. Green tea extracts have been shown to impact mechanisms associated with cancer, diabetes, neurodegenerative disease, cardiovascular disease, muscular disease and inflammation. We were the first to uncover a novel and key mechanism of action of the major flavonoid isolated from green tea, (-)-epigallocatechin-3-gallate or EGCG.

We designed our drug candidates based on EGCG, with the goal of improving bioavailability and anti-tumor potency, while retaining a high level of safety.

Our drug candidates affect important proteins and signalling pathways extensively studied in animal models and humans, and linked to the conditions that we seek to address.

Our initial strategy seeks to study our drug candidates in patients with gynecologic tumors. The most common gynecologic tumor is a benign hormone-dependent tumor called leiomyoma. These are also referred to as uterine fibroids and are associated with clinical symptoms including heavy bleeding, pain, urinary incontinence, and infertility. The only cure at present is hysterectomy. Our long-term goal is to develop a drug with a suitable safety and efficacy profile that would allow the long-term management of symptomatic uterine fibroids thus avoiding the need for hysterectomy.

Based on our initial data, we also expect our drug candidates to find application in other disorders such as endometriosis, as well as other gynecologic tumors such as ovarian cancer.

Our Mission

Our mission is to leverage the growing body of positive human clinical data with green tea extracts, as a risk mitigation strategy to develop novel chemical entities with enhanced potency and bioavailability and pharmaceutical properties, thus improving clinical outcomes and establishing new standard-of-care in areas of significant unmet medical need.